🚨 ?another practice-changing #ESMO2026 result!

Dr Adam Januszewski· @AdamJanuszewski · X·2026-10-26 00:06· 1 天前评分70

正文 · 原文

Phase III #SAFFRON establishes osi + savo as a NEW SOC for EGFRm/MET+ #NSCLC progressing on osimertinib.

📈 PFS: 7.6 vs 5.4m (HR 0.55)
📈 significant OS: 17.8 vs 12.9m (HR 0.68)

🔬 Importance of RE-BIOPSY at progression

11 浏览 · 0 赞 · 0 转发 · 0 回复